Irbesartán Liconsa

Irbesartan, the active ingredient in Irbesartán Liconsa, is an angiotensin II receptor blocker presented as an oral dosage form for systemic use. It is used to lower high blood pressure and to help delay renal disease progression in patients with diabetic nephropathy.

GNH USA supplies Irbesartán Liconsa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its distribution network ensures timely delivery and compliance with local regulatory requirements.

Irbesartan is an angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system.

- Hypertension: reduces systolic and diastolic blood pressure, improving cardiovascular risk profile. - Diabetic nephropathy: slows progression of renal impairment in patients with type 2 diabetes, reducing proteinuria. - Proteinuria: decreases urinary protein excretion associated with chronic kidney disease.

Common side effects are generally mild and transient.

Common Side Effects: - Dizziness - Headache - Fatigue - Nausea

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe hyperkalemia (elevated blood potassium) - Acute kidney injury (sudden decline in renal function)

Before initiating therapy, clinicians should consider several safety measures.

- Blood pressure monitoring: ensure target levels are achieved without excessive hypotension. - Renal function assessment: check serum creatinine and eGFR periodically. - Serum potassium: monitor for hyperkalemia, especially when combined with potassium‑sparing agents. - Pregnancy: avoid use during pregnancy (Category D) due to fetal toxicity risk. - Elderly patients: start at lower dose and titrate cautiously. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): increased risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors: concurrent use can lead to additive effects on potassium and renal function.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect and impair renal function. - Thiazide diuretics: can enhance antihypertensive response, requiring dose adjustment. - Lithium: may increase lithium levels, necessitating serum monitoring.